01.29.10
Cephalon, Inc. has promoted three executives, Kevin Buchi, Wilco Groenhuysen and Alain Aragues.
Mr. Buchi will serve as chief operating officer, responsible for worldwide pharmaceutical operations, worldwide technical operations, investor relations and business development. Mr. Buchi joined the company in 1991 and became chief financial officer in 1996.
"During his 18 years at Cephalon, Kevin has been instrumental in building the company's global pharmaceutical business," said Frank Baldino, Jr., Ph.D., chairman and chief executive officer. "In his role as CFO, he orchestrated nine acquisitions and built a strong financial infrastructure."
Mr. Groenhuysen is promoted to executive vice president and chief financial officer, responsible for worldwide finance, commercial operations and risk management. Mr. Groenhuysen will report directly to Dr. Baldino, Jr. Mr. Groenhuysen joined the company in August 2007 as senior vice president of finance.
"In his two years with Cephalon, Wilco has improved our internal financial reporting and strengthened our global finance organization. I have confidence in Wilco's ability to lead the company's financial organization," added Dr. Baldino.
Mr. Aragues will serve as executive vice president and president of Cephalon Europe. Mr. Aragues joined Cephalon in 2002 to lead the company's expansion in France following its 2001 acquisition of Group Lafon, and was appointed president of Cephalon Europe in 2005.
"Alain was recruited to build our European business and under his direction, our European business has grown to include 50 countries and more than 30 products.During his tenure, our European sales have more than tripled.I am confident that these leadership changes will bring the company's performance to a new level as we expand globally," said Dr. Baldino.
Mr. Buchi will serve as chief operating officer, responsible for worldwide pharmaceutical operations, worldwide technical operations, investor relations and business development. Mr. Buchi joined the company in 1991 and became chief financial officer in 1996.
"During his 18 years at Cephalon, Kevin has been instrumental in building the company's global pharmaceutical business," said Frank Baldino, Jr., Ph.D., chairman and chief executive officer. "In his role as CFO, he orchestrated nine acquisitions and built a strong financial infrastructure."
Mr. Groenhuysen is promoted to executive vice president and chief financial officer, responsible for worldwide finance, commercial operations and risk management. Mr. Groenhuysen will report directly to Dr. Baldino, Jr. Mr. Groenhuysen joined the company in August 2007 as senior vice president of finance.
"In his two years with Cephalon, Wilco has improved our internal financial reporting and strengthened our global finance organization. I have confidence in Wilco's ability to lead the company's financial organization," added Dr. Baldino.
Mr. Aragues will serve as executive vice president and president of Cephalon Europe. Mr. Aragues joined Cephalon in 2002 to lead the company's expansion in France following its 2001 acquisition of Group Lafon, and was appointed president of Cephalon Europe in 2005.
"Alain was recruited to build our European business and under his direction, our European business has grown to include 50 countries and more than 30 products.During his tenure, our European sales have more than tripled.I am confident that these leadership changes will bring the company's performance to a new level as we expand globally," said Dr. Baldino.